FDA panel backs unapproved peptides in narrow vote

Good morning, healthcare professional.

Regulatory upheaval dominated the news cycle this week as an FDA advisory committee delivered a controversial endorsement of compounding unapproved peptides, while GSK celebrated a rapid approval for its first lung cancer therapy. Meanwhile, Eli Lilly advanced its next-generation obesity drug toward regulatory submission, and the Trump administration threatened new tariffs on imported generic medications.

These developments signal shifting dynamics in drug regulation, market competition, and pharmaceutical supply chains. From compounding pharmacy oversight to international trade policy, the decisions made now will reshape how medications reach patients and at what cost.

In today's healthcare digest:

• FDA advisory panel narrowly endorses compounding of controversial peptides like BPC-157
• GSK secures speedy lung cancer drug approval following $10.6 billion Nuvalent acquisition
• Eli Lilly plans regulatory submission for obesity drug retatrutide despite cardiovascular questions
• Trump administration threatens tariffs on imported generic drugs, risking price increases

FDA Panel Backs Controversial Peptides in Narrow Vote

An FDA advisory committee narrowly voted to allow compounding pharmacies to produce unapproved peptides including BPC-157 and KPV, delivering a win for RFK Jr. and peptide advocates. The decision represents a significant shift in how regulators approach compounding pharmacy oversight.

Unpacked:

• The advisory panel's vote was notably close, reflecting deep divisions over peptide safety and efficacy evidence.
• The decision affects compounding pharmacies' ability to produce peptides that lack FDA approval for specific uses.
• Critics warn this could weaken drug safety oversight while supporters claim it expands patient access.

GSK Scores First Lung Cancer Approval After Nuvalent Deal

GSK received FDA approval for Jideytro, a ROS1-targeted lung cancer therapy, marking the company's entry into oncology and a quick regulatory payoff from its $10.6 billion Nuvalent acquisition. The speedy approval timeline demonstrates the drug's clinical promise for ROS1-positive patients.

Unpacked:

• Jideytro targets ROS1-positive non-small cell lung cancer, a specific genetic mutation affecting select patients.
• The approval came remarkably fast following GSK's massive acquisition of Nuvalent earlier this year.
• This marks GSK's first lung cancer treatment, expanding its oncology portfolio into a competitive market.

Lilly Advances Obesity Drug Despite Heart Benefit Questions

Eli Lilly announced plans to seek FDA approval for retatrutide, its next-generation obesity medication, based on new clinical data. However, the company acknowledged uncertainty around cardiovascular benefits, a key selling point for competing weight-loss drugs.

Unpacked:

• Retatrutide is a triple-G receptor agonist representing Lilly's next wave in obesity treatment innovation.
• The cardiovascular benefit question creates potential competitive disadvantage against drugs with proven heart protection.
• Lilly's decision to proceed with regulatory submission signals confidence in the drug's weight-loss efficacy data.

Trump Threatens Tariffs on Imported Generic Drugs

The Trump administration announced potential tariffs on imported generic medications, raising concerns about drug pricing and supply chain disruption. The policy could directly impact medication costs for patients who rely on affordable generic alternatives.

Unpacked:

• Generic drugs constitute the majority of prescriptions filled in the U.S., with many manufactured overseas.
• Tariffs would likely increase costs for pharmacies, insurers, and ultimately patients at the counter.
• The proposal connects to broader debates about pharmaceutical manufacturing, supply chain resilience, and national security.

The Shortlist

• Scribe Therapeutics secured $129 million in a rare gene editing IPO, pushing forward PCSK9 and lipoprotein programs.

• Johnson & Johnson reported an 89% reduction in myeloma progression risk with its bispecific antibody combination in phase 3 trials.

• Arrowhead Pharmaceuticals achieved best-case scenario results with plozasiran for severe hypertriglyceridemia in latest clinical data.

• Sanofi faced FDA criticism for promotional emails that gave a misleading impression of Beyfortus use in RSV prevention.

• Senate health committee delayed votes on CDC director nominee amid scrutiny of qualifications and policy positions.